-
公开(公告)号：US20240335383A1
公开(公告)日：2024-10-10
申请号：US18700066
申请日：2022-10-11
申请人： NewImmune II, LLC
发明人： Brian HORSBURGH , Mark David MOODY
IPC分类号： A61K9/127 , A61K31/4745 , A61K38/20 , A61K47/10 , A61K47/24 , A61K47/28 , A61K47/69 , A61P35/00
CPC分类号： A61K9/1271 , A61K31/4745 , A61K38/2013 , A61K47/10 , A61K47/24 , A61K47/28 , A61K47/6951 , A61P35/00
摘要： The present disclosure relates to nanoparticles and nanoparticulate compositions; methods of preparing such nanoparticles and nanoparticulate compositions; and associated methods of medical treatment and uses of such nanoparticles and nanoparticulate compositions for medical treatment, including the use of such nanoparticles for the manufacture of medicaments for medical treatment.
-
2.发明授权公开(公告)号：US12090156B2
公开(公告)日：2024-09-17
申请号：US18573439
申请日：2023-02-15
申请人： Institute of Ophthalmology Affiliated to Shandong First Medical University (Shandong Institute of
发明人： Weiyun Shi , Qingjun Zhou , Hongwei Wang , Bining Zhang
摘要： In view of the problem that the current prevention and treatment manners for corneal neovascularization (CNV) may cause complications, the present disclosure provides an application of CB-839 in preparation of a drug for inhibiting CNV. The CB-839-loaded drug of the present disclosure can significantly inhibit CNV in mice and reduce the infiltration of inflammatory cells without obvious side effects, which makes up for the shortcoming of the prior art.
-
公开(公告)号：US20240285533A1
公开(公告)日：2024-08-29
申请号：US18593245
申请日：2024-03-01
发明人： Mirko Hennig , Ali Ahmed Alfaifi , Sakya Sing Mohapatra , Daniella Ishimaru , Vladimir Grigor'evich Kharitonov , Julia Jung-un Baek , Shuang Li , David J. Lockhart , Brandon A. Wustman , Yufeng Wang , Joseph S. Cefalu
CPC分类号： A61K9/145 , A61K9/0078 , A61K47/24 , A61K47/26 , A61K47/28 , A61K48/0008 , C07K14/705
摘要： Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for cystic fibrosis (CF), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject, wherein the LNPs comprise mRNA encoding a Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein.
-
公开(公告)号：US12064479B2
公开(公告)日：2024-08-20
申请号：US18324097
申请日：2023-05-25
IPC分类号： A61K39/395 , A61K39/215 , A61K39/385 , A61K47/24 , A61K47/28 , A61K47/69
CPC分类号： A61K39/385 , A61K39/215 , A61K47/24 , A61K47/28 , A61K47/6929 , A61K47/6935
摘要： The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
-
公开(公告)号：US20240269229A1
公开(公告)日：2024-08-15
申请号：US18692273
申请日：2022-09-14
申请人： ADVAPHARM GMBH
发明人： Andreas SCHUTZ , Helmut WOLF
摘要： Novel pharmaceutical liposomal formulation of lipopeptides are provided as well as their uses and preparation.
-
公开(公告)号：US12059468B2
公开(公告)日：2024-08-13
申请号：US17368246
申请日：2021-07-06
IPC分类号： A61K31/7004 , A61K31/70 , A61K31/7052 , A61K31/7088 , A61K31/713 , A61K47/16 , A61K47/22 , A61K47/28 , A61K47/54 , A61K47/60 , C07H21/02 , A61K48/00
CPC分类号： A61K47/28 , A61K31/70 , A61K31/7004 , A61K31/7052 , A61K31/7088 , A61K31/713 , A61K47/16 , A61K47/22 , A61K47/543 , A61K47/549 , A61K47/60 , C07H21/02 , A61K48/00 , Y02A50/30 , Y02P20/55
摘要： The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below:
The present invention also provides a phosphorothioate-modified oligonucleotide comprising a structure having formula (CIII):-
公开(公告)号：US20240261381A1
公开(公告)日：2024-08-08
申请号：US18008877
申请日：2021-06-11
发明人： Sanne BEVERS , Stefaan DE KOKER , Raymond Michel SCHIFFELERS , Sander Alexander Antonius KOOIJMANS
CPC分类号： A61K39/001117 , A61K9/5123 , A61K9/5146 , A61K39/001102 , A61K47/24 , A61K47/28 , A61P35/00 , A61P37/04 , A61K2039/53 , A61K2039/575
摘要： The present invention relates to the field of lipid nanoparticles (LNP); more specifically comprising an ionizable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in comprising less than about 1 mol % of a C14-PEG2000 lipid; as well as particular percentages of the other lipids. The present invention provides use of the LNP's for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.
-
公开(公告)号：US20240254491A1
公开(公告)日：2024-08-01
申请号：US18581511
申请日：2024-02-20
发明人： Akin Akinc , Jeffrey Zuber
IPC分类号： C12N15/113 , A61K31/713 , A61K47/14 , A61K47/18 , A61K47/28
CPC分类号： C12N15/113 , A61K31/713 , A61K47/14 , A61K47/18 , A61K47/28 , C12N2310/14 , C12N2310/312 , C12N2310/315 , C12N2310/321 , C12N2310/322
摘要： The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the beta-catenin (CTNNB1) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CTNNB1 gene and to methods of preventing and treating a CTNNB1-associated disorder, e.g., cancer, e.g., hepatocellular carcinoma.
-
公开(公告)号：US12006500B2
公开(公告)日：2024-06-11
申请号：US17157920
申请日：2021-01-25
申请人： Sirnaomics, Inc.
发明人： Danny Tang , Xueping Chen , Patrick Y. Lu , Vera Simonenko , David Evans , John Xu , Deling Wang , Alan Lu
IPC分类号： C12N15/113 , A61K9/51 , A61K31/713 , A61K47/28 , A61K47/69 , A61P31/14
CPC分类号： C12N15/113 , A61K9/513 , A61K31/713 , A61K47/28 , A61K47/6931 , A61P31/14
摘要： Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.
-
公开(公告)号：US12005142B2
公开(公告)日：2024-06-11
申请号：US17264552
申请日：2019-07-31
发明人： Keelung Hong , Yi-Yu Lin , Hao-Wen Kao
IPC分类号： A61K9/127 , A61K9/00 , A61K31/135 , A61K31/439 , A61K47/24 , A61K47/26 , A61K47/28
CPC分类号： A61K9/1273 , A61K9/0019 , A61K31/135 , A61K31/439 , A61K47/24 , A61K47/26 , A61K47/28
摘要： The present invention relates to a pharmaceutical composition comprising at least one liposome and a therapeutic agent for treating depression or anxiety, with a therapeutic agent to lipid ratio equal to or higher than about 0.15. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the therapeutic agent. Also provided is the method for treating depression or anxiety using the pharmaceutical composition disclosed herein.
-
-
-
-
-
-
-
-
-
搜索结果
807 条记录 (耗时 0.041 秒)
